Talphera (NASDAQ:TLPH) Stock Price Down 1.9% – Here’s What Happened

Talphera, Inc. (NASDAQ:TLPH) shares traded down 1.9% on Wednesday . The company traded as low as $0.8030 and last traded at $0.8312. 77,131 shares changed hands during mid-day trading, a decline of 59% from the average session volume of 190,092 shares. The stock had previously closed at $0.8470.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Talphera in a report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Talphera Trading Down 1.9%

The stock has a market capitalization of $41.60 million, a P/E ratio of -2.25 and a beta of 0.56. The stock’s fifty day moving average price is $0.82 and its two-hundred day moving average price is $1.04.

Talphera (NASDAQ:TLPH) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. As a group, analysts expect that Talphera, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Vincent J. Angotti purchased 213,310 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average cost of $0.59 per share, for a total transaction of $125,852.90. Following the acquisition, the chief executive officer directly owned 800,705 shares of the company’s stock, valued at $472,415.95. This represents a 36.31% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Badri N. Dasu purchased 35,000 shares of the stock in a transaction that occurred on Thursday, February 12th. The shares were purchased at an average price of $0.81 per share, with a total value of $28,350.00. Following the completion of the acquisition, the insider directly owned 76,230 shares in the company, valued at $61,746.30. The trade was a 84.89% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have purchased 433,674 shares of company stock valued at $304,348. 5.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Talphera

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Group One Trading LLC raised its holdings in Talphera by 3,224.0% during the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after buying an additional 29,500 shares during the last quarter. Virtu Financial LLC bought a new stake in Talphera during the 3rd quarter valued at $29,000. Mariner LLC raised its holdings in Talphera by 132.0% during the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after buying an additional 33,000 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in Talphera during the 4th quarter valued at $42,000. Finally, Dauntless Investment Group LLC bought a new stake in Talphera during the 3rd quarter valued at $89,000. 37.67% of the stock is currently owned by institutional investors.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.